Table 1. Open in a separate window. Table 2. Table 3. Role of cognitive impairment in the concept of NEDA The appearance of a wide array of immunomodulatory drugs for treating MS has resulted in the need for evaluating the efficacy of such drugs. Neuropsychiatric disorders It is widely documented that patients with MS have a higher risk of experiencing emotional disorders.
Neuropsychiatric Manifestations of Multiple Sclerosis
Conflicts of interest The authors declared no potential conflicts of interest with respect to this review. Funding The authors received no financial support for this review. References 1. J Int Neuropsychol Soc ; 12 : — Langdon DW. Cognition in multiple sclerosis. Curr Opin Neurol ; 24 : — Epidemiological characteristics of cognitive impairment of multiple sclerosis patients in a Latin American country.
J Clin Exp Neuropsychol ; 33 : — Cognitive and neuropsychiatric disorders among multiple sclerosis patients from Latin America: results of the Relaccem study. Mult Scler Relat Disord ; 3 : — Cognitive impairment in patients with multiple sclerosis from Western Mexico. Revista Mexicana de Neurociencia ; 16 : 1— Validation of the multiple sclerosis neuropsychological screening questionnaire in Argentina. Mult Scler ; 15 : — Culture and systems of thought: holistic versus analytic cognition. Psychol Rev ; : — Rosselli M, Ardila A.
The impact of culture and education on non-verbal neuropsychological measurements: a critical review. Brain Cogn ; 52 : — Cognitive impairment in multiple sclerosis. Lancet Neurol ; 7 : — Patti F.
Mult Scle ; 15 : 2—8. Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes. Mult Scler 1 October Achiron A, Barak Y. Cognitive impairment in probable multiple sclerosis. J Neurol Neurosurg Psychiatry ; 74 : — Cognitive dysfunction in multiple sclerosis: a review of recent developments. Curr Opin Neurol ; 16 : — Cognitive profile of patients with relapsing remitting multiple sclerosis. Arq Neuropsiquiatr ; 57 : — Rao SM. Neurol Sci ; 36 : — Differences in cognitive impairment of relapsing remitting, secondary, and primary progressive MS.
Neurology ; 63 : — Differential patterns of memory performance in relapsing, remitting and secondary progressive multiple sclerosis. Neurol India ; 54 : — Discriminant analysis of the cognitive performance profile of MS patients differentiates their clinical course. J Neurol ; : — School performance as a marker of cognitive decline prior to diagnosis of multiple sclerosis.
- The Thermodynamics of Phase and Reaction Equilibria.
- Among the Ten Thousand Things: A Novel.
- Grocery Warning: How to Recognize and Avoid the Groceries that Cause Cancer, Diabetes, Heart Disease, High Cholesterol, High Blood Pressure, and Other Common Diseases;
- Genocide: A Normative Account;
Mult Scler ; 21 : — Cognitive reserve moderates decline in information processing speed in multiple sclerosis patients. J Int Neuropsychol Soc ; 16 : — Pirko I, Nosewhorty H. Demyelinating disorders of the Central Nervous System. In: Goetz CG, editor. Textbook of Clinical Neurology , 2nd ed.
Philadelphia: Elsevier, , pp. Marrie RA. Demographic, genetic and environmental factors that modify disease course.
Emotional Changes : National Multiple Sclerosis Society
Neurologic Clin ; — Comparisons of Latinos, African Americans, and Caucasians with multiple sclerosis. Ethn Dis ; 20 : — Mult Scler ; 9 : — Multiple sclerosis in Caucasians and Latino Americans. Autoimmunity ; 44 : — Mov Disord ; 31 : — Ardila A. Cultural values underlying psychometric cognitive testing.
Neuropsychol Rev ; 15 : — Cognitive but not affective theory of mind deficits in mild relapsing—remitting multiple sclerosis.
Cogn Behav Neurol ; 27 : 25— The relationship between alexithymia, empathy and moral judgment in patients with multiple sclerosis. Eur J Neurol ; 22 : — Vanotti S. Buenos Aires: Buenos University, Unemployment in multiple sclerosis: the contribution of personality and disease. Mult Scler ; 18 : — Self-rated health and employment status in patients with multiple sclerosis.
Disabil Rehabil ; 32 : — Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis. Mult Scler ; 23 : — Mult Scler ; 5 : — Spreen O, Strauss E. A compendium of neuropsychological tests , 2nd ed. Limitations of the paced auditory serial addition test as a measure of working memory in patients with multiple sclerosis.
J Int Neuropsychol Soc ; 7 : — Gronwall DM. Paced auditory serial-addition task: a measure of recovery from concussion. Percept Mot Skills ; 44 : — Appl Neuropsychol Adult ; 23 : — Mult Scler ; 12 : — The brief repeatable battery of neuropsychological tests: normative values allow application in multiple sclerosis clinical practice. Mult Scler ; 7 : — Rev chil neuropsicol ; 6 : 81— The paced auditory serial addition test: to what extent is it performed as instructed, and is it associated with disease course.
Mult Scler ; 11 : 85— Arq Neuropsiquiatr ; 62 : — Reliable screening for neuropsychological impairment in MS. Mult Scler ; 10 : — BMC Neurol ; 12 : Smith A. Symbol digit modalities test: Manual. California Verbal Learning Test Manual , 2nd ed. Benedict RHB.
Brief visuospatial memory test — Revised: Professional manual. Clin Neuropsychol ; 26 : — The brief international cognitive assessment for multiple sclerosis BICAMS : normative values with gender, age and education corrections in the Italian population. BMC Neurol ; 10 : The Hungarian validation of the brief international cognitive assessment for multiple sclerosis BICAMS battery and the correlation of cognitive impairment with fatigue and quality of life.
Mult Scler Relat Disord ; 4 : — Brief international cognitive assessment for multiple sclerosis BICAMS : Canadian contribution to the international validation project. J Neurol Sci ; 15 : — Clin Neuropsychol ; 29 : — Clin Neuropsychol ; 30 : — A brief neuropsychological screening test battery for cognitive dysfunction in Brazilian multiple sclerosis patients. Brain Inj ; 22 : — Validity of the symbol digit modalities test as a cognition performance outcome measure for multiple sclerosis.
Cognitive impairment in patients with multiple sclerosis using the brief repeatable battery—neuropsychology test. Screening for cognitive impairment in multiple sclerosis using the symbol digit modalities test. Mult Scler ; 13 : 52— Normatization of the symbol digit modalities test — oral version in a Latin American country. Appl Neuropsychol Adult ; 22 : 46— The effect of culture on two information-processing speed tests. Appl Neuropsychol Adult ; 22 : — Treatment optimization in multiple sclerosis.
The diagnosis of depression, which may be complicated by other MS symptoms like fatigue and cognitive disturbance, requires careful differential diagnosis. A Cochrane review emphasizes the efficacy of tricyclic antidepressants as well as of serotonin reuptake inhibitors SSRI in depressive patients with other medical illness.
- The Secrets of D-Day: A Masterful History of One of the Most Important Days of the 20th Century.
- Convective Heat Transfer: Solved Problems!
- Cognitive and neuropsychiatric disorders among MS patients from Latin America.
- The Neuropsychiatry of Multiple Sclerosis – What Should Psychiatrists Know?.
The treatment performs magnetic stimulation of brain structures and networks and brings significant improvement to patients. In a double-blind sham-controlled BrainsWay Deep TMS study, patients suffering from MS showed significant improvements in measures of fatigue and depressive symptoms, following a 6 week Deep TMS treatment over the motor cortex. In another double-blind sham-controlled Deep TMS study, it was found the real Deep TMS treatment led to significant improvements in both speed and endurance of walking ability in MS patients.
While the status of our regulatory approvals is generally updated on this website, in order to verify whether BrainsWay is currently approved in your area for the treatment of this indication, please contact us at info brainsway. Multiple Sclerosis MSC Multiple Sclerosis MSc is an inflammatory demyelinating condition of the central nervous system that is mostly considered to be autoimmune.